{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:02:24Z","timestamp":1789603344228,"version":"build-2803163510"},"reference-count":346,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.apsb.2026.06.045","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:41:56Z","timestamp":1782517316000},"page":"5566-5591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tuning epigenetics to enhance cancer virotherapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Yuanyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4346-0701","authenticated-orcid":false,"given":"Lanyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunting","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-8013","authenticated-orcid":false,"given":"Zhi-Jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.06.045_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib2","series-title":"Handbook of global health","first-page":"459","article-title":"Global burden of cancer","author":"Ngoma","year":"2021"},{"key":"10.1016\/j.apsb.2026.06.045_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28729","article-title":"Application of oncolytic virus in tumor therapy","volume":"95","author":"Huang","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib8","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.apsb.2026.06.045_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003578","article-title":"Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients","volume":"4","author":"Adair","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib10","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3390\/cancers13112761","article-title":"Oncolytic viruses in combination therapeutic approaches with epigenetic modulators: past, present, and future perspectives","volume":"13","author":"Chianese","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.06.045_bib11","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.ymthe.2022.02.006","article-title":"Histone modifiers at the crossroads of oncolytic and oncogenic viruses","volume":"30","author":"Murphy","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/v8010009","article-title":"Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade","volume":"8","author":"Marchini","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2026.06.045_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41698-025-01003-7","article-title":"Epigenetic regulators in cancer therapy and progression","volume":"9","author":"Marei","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.06.045_bib16","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2026.06.045_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3892\/mmr.2015.3355","article-title":"Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer","volume":"12","author":"Han","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.06.045_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for tumor therapy","volume":"15","author":"Bell","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.apsb.2026.06.045_bib20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and biosafety of oncolytic virotherapy","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: a current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/mt.2011.71","article-title":"Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer","volume":"19","author":"Khare","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5483\/BMBRep.2021.54.1.257","article-title":"Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7","volume":"54","author":"Kim","year":"2021","journal-title":"BMB Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib28","article-title":"Viral warriors: unlocking the immune system's potential with oncolytic viruses in cancer immunotherapy","volume":"33","author":"Ghavimi","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2007.02.006","article-title":"Epigenetics: a landscape takes shape","volume":"128","author":"Goldberg","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib30","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: targeting epigenetic marks in cancer treatment","volume":"14","author":"Miranda","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.apsb.2026.06.045_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.apsb.2026.06.045_bib32","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1158\/0008-5472.CAN-23-2785","article-title":"The DNA methyltransferase inhibitor 5-aza-4\u2032-thio-2\u2032-deoxycytidine induces C>G transversions and acute lymphoid leukemia development","volume":"84","author":"Bertoli","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib34","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.18632\/oncotarget.1821","article-title":"The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma","volume":"5","author":"Maes","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2026.06.045_bib35","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib37","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.0505585102","article-title":"Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim","volume":"102","author":"Zhao","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.06.045_bib38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib39","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib40","article-title":"EZH2 inhibitors suppress colorectal cancer by regulating macrophage polarization in the tumor microenvironment","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib42","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.3748\/wjg.v26.i26.3737","article-title":"Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression","volume":"26","author":"Zheng","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2026.06.045_bib43","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.06.045_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","article-title":"SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance","volume":"21","author":"Jensen-Pergakes","year":"2022","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.06.045_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/onc.2015.92","article-title":"The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia","volume":"35","author":"Giotopoulos","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.06.045_bib46","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2026.06.045_bib47","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","article-title":"Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for leukemia therapy","volume":"75","author":"Picaud","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib48","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1128\/AAC.02617-13","article-title":"Tranylcypromine reduces herpes simplex virus 1 infection in mice","volume":"58","author":"Yao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2026.06.045_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fvets.2018.00034","article-title":"Effect of a histone demethylase inhibitor on equine herpesvirus-1 activity","volume":"5","author":"Tallmadge","year":"2018","journal-title":"in vitro. Front Vet Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1541-7786.MCR-21-0390","article-title":"Exquisite sensitivity to dual BRG1\/BRM ATPase inhibitors reveals broad SWI\/SNF dependencies in acute myeloid leukemia","volume":"20","author":"Rago","year":"2022","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib51","article-title":"Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells","volume":"10","author":"Park","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130208","article-title":"PEG\u2013ASO conjugates for efficient targeted delivery and migration inhibition in cancer cell","volume":"122","author":"Zhao","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2026.06.045_bib53","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.3390\/ijms24087235","article-title":"Harnessing epigenetics for breast cancer therapy: the role of DNA methylation, histone modifications, and microRNA","volume":"24","author":"Szczepanek","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652160","article-title":"Epigenetic modifiers: anti-neoplastic drugs with immunomodulating potential","volume":"12","author":"Maes","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib55","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1021\/acs.molpharmaceut.8b00554","article-title":"Potent activity of the bromodomain inhibitor OTX015 in multiple myeloma","volume":"15","author":"Shi","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2026.06.045_bib56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.30412","article-title":"Promising in vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts","volume":"140","author":"V\u00e1zquez","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00432-022-03983-6","article-title":"A phase 1 study of IDH305 in patients with IDH1(R132)-mutant acute myeloid leukemia or myelodysplastic syndrome","volume":"149","author":"DiNardo","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib58","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cgt.2008.81","article-title":"The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells","volume":"16","author":"Katsura","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092919","article-title":"Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells","volume":"9","author":"Cody","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.06.045_bib60","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.3390\/ijms22168582","article-title":"Oncolytic bovine herpesvirus 1 inhibits human lung adenocarcinoma A549 cell proliferation and tumor growth by inducing DNA damage","volume":"22","author":"Qiu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.16032","article-title":"Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell\u2013cell fusion","volume":"115","author":"Nakatake","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib62","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10495-006-0009-9","article-title":"Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity","volume":"12","author":"VanOosten","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.apsb.2026.06.045_bib63","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/mt.2008.155","article-title":"Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses","volume":"16","author":"Otsuki","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib64","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ymthe.2019.04.008","article-title":"Potentiating oncolytic virus-induced immune-mediated tumor cell killing using histone deacetylase inhibition","volume":"27","author":"Jennings","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib65","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/v11060562","article-title":"H-1 parvovirus as a cancer-killing agent: past, present, and future","volume":"11","author":"Bretscher","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2026.06.045_bib66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/v11050431","article-title":"Histone deacetylase inhibitors enhance cell killing and block interferon-beta synthesis elicited by infection with an oncolytic parainfluenza virus","volume":"11","author":"Fox","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2026.06.045_bib67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omto.2017.05.002","article-title":"Reolysin and histone deacetylase inhibition in the treatment of head and neck squamous cell carcinoma","volume":"5","author":"Jaime-Ramirez","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apsb.2026.06.045_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.19","article-title":"Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma","volume":"2","author":"Ruf","year":"2015","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apsb.2026.06.045_bib69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/cgt.2011.11","article-title":"Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells","volume":"18","author":"Kim","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00626-19","article-title":"SIRT1 modulates the sensitivity of prostate cancer cells to vesicular stomatitis virus oncolysis","volume":"93","author":"Muscolini","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00262-025-04252-4","article-title":"Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I\/cGAS\u2013STING","volume":"75","author":"Sakamoto","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2026.06.045_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216063","article-title":"Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma","volume":"556","author":"Lin","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.06.045_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.4","article-title":"Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma","volume":"2","author":"Cuddington","year":"2015","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apsb.2026.06.045_bib74","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1158\/1078-0432.CCR-12-3588","article-title":"DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas","volume":"19","author":"Okemoto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib75","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/CAD.0000000000001525","article-title":"DNA methyltransferase inhibitor 5-azacytidine enhances neuroblastoma cell lysis by an oncolytic parainfluenza virus","volume":"34","author":"Kedarinath","year":"2023","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.apsb.2026.06.045_bib76","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41417-020-0199-2","article-title":"Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid\/rhabdoid tumor cells","volume":"28","author":"Thakur","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-21-0240","article-title":"Novel group C oncolytic adenoviruses carrying a miRNA inhibitor demonstrate enhanced oncolytic activity in vitro and in vivo","volume":"21","author":"Doerner","year":"2022","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.06.045_bib78","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/cancers13133233","article-title":"Inhibition of miR-222 by oncolytic adenovirus-encoded miRNA sponges promotes viral oncolysis and elicits antitumor effects in pancreatic cancer models","volume":"13","author":"Raimondi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.06.045_bib79","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ymthe.2018.09.016","article-title":"Bioselection reveals miR-99b and miR-485 as enhancers of adenoviral oncolysis in pancreatic cancer","volume":"27","author":"Rovira-Rigau","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib80","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41467-022-29526-8","article-title":"Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy","volume":"13","author":"Wedge","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.omto.2020.10.012","article-title":"Expression of oncolytic adenovirus-encoded RNAi molecules is most effective in a pri-miRNA precursor format","volume":"19","author":"Brachtlova","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apsb.2026.06.045_bib82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13046-021-01865-2","article-title":"Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion","volume":"40","author":"Wu","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib83","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/1535-7163.MCT-16-0096","article-title":"An artificially designed interfering lncRNA expressed by oncolytic adenovirus competitively consumes oncomiRs to exert antitumor efficacy in hepatocellular carcinoma","volume":"15","author":"Li","year":"2016","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.06.045_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canlet.2020.03.012","article-title":"Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer","volume":"479","author":"Ang","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.06.045_bib85","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/microorganisms11030688","article-title":"LncRNA 8244-ssc-miR-320-CCR7 regulates IFN-\u03b2 during SVA infecting PK-15 cells","volume":"11","author":"Tang","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.apsb.2026.06.045_bib86","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3892\/mmr.2024.13245","article-title":"Dual-regulated oncolytic adenovirus carrying ERCC1-siRNA gene possesses potent antitumor effect on ovarian cancer cells","volume":"30","author":"Zhao","year":"2024","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib87","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1002\/jcb.27863","article-title":"The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability","volume":"120","author":"Li","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2026.06.045_bib88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/cas.14721","article-title":"Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma","volume":"112","author":"Sugii","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virusres.2013.12.021","article-title":"Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells","volume":"181","author":"Fang","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib90","article-title":"Antitumor effects of oncolytic adenovirus-carrying siRNA targeting potential oncogene EphA3","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.06.045_bib91","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/gt.2009.99","article-title":"Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope","volume":"16","author":"Matsuda","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib92","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/ijms25021265","article-title":"Inhibition of bromodomain proteins enhances oncolytic HAdVC5 replication and efficacy in pancreatic ductal adenocarcinoma (PDAC) models","volume":"25","author":"Miao","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib93","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/rej.2012.1324","article-title":"The role of DNA methylation in aging, rejuvenation, and age-related disease","volume":"15","author":"Johnson","year":"2012","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0749-0704(18)30390-7","article-title":"Airway management: considerations in the trauma patient","volume":"6","author":"Grande","year":"1990","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.apsb.2026.06.045_bib95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-019-0079-0","article-title":"Accumulation of genetic and epigenetic alterations in normal cells and cancer risk","volume":"3","author":"Takeshima","year":"2019","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib96","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib97","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/890","article-title":"Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases","volume":"19","author":"Okano","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib98","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/hmg\/9.16.2395","article-title":"The DNA methyltransferases of mammals","volume":"9","author":"Bestor","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib99","first-page":"631","article-title":"The role of mammalian DNA methyltransferases in the regulation of gene expression","volume":"10","author":"Turek-Plewa","year":"2005","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.apsb.2026.06.045_bib100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41588-022-01040-z","article-title":"DNMT3A-dependent DNA methylation is required for spermatogonial stem cells to commit to spermatogenesis","volume":"54","author":"Dura","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib101","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.1120976","article-title":"Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2","volume":"311","author":"Goll","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.045_bib102","first-page":"2989","article-title":"DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer","volume":"33","author":"Gnyszka","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108434","article-title":"Targeting tumor endothelial cells with methyltransferase inhibitors: mechanisms of action and the potential of combination therapy","volume":"247","author":"Zhou","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib104","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib106","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026948","article-title":"DNA hypomethylating drugs in cancer therapy","volume":"7","author":"Sato","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib107","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1038\/s41598-023-32509-4","article-title":"DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors","volume":"13","author":"Laranjeira","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.11","article-title":"Writing, erasing and reading histone lysine methylations","volume":"49","author":"Hyun","year":"2017","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib109","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s43556-025-00275-6","article-title":"Histone and non-histone lactylation: molecular mechanisms, biological functions, diseases, and therapeutic targets","volume":"6","author":"Peng","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.apsb.2026.06.045_bib110","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.7150\/ijbs.91492","article-title":"Histone lactylation: from tumor lactate metabolism to epigenetic regulation","volume":"20","author":"Yu","year":"2024","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib111","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13478","article-title":"Lactate-induced protein lactylation: a bridge between epigenetics and metabolic reprogramming in cancer","volume":"56","author":"Wang","year":"2023","journal-title":"Cell Prolif"},{"key":"10.1016\/j.apsb.2026.06.045_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib113","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00726-004-0087-3","article-title":"Acetylation of proteins as novel target for antitumor therapy: review article","volume":"26","author":"Di Gennaro","year":"2004","journal-title":"Amino Acids"},{"key":"10.1016\/j.apsb.2026.06.045_bib114","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.abb.2004.09.003","article-title":"Structure and functions of the GNAT superfamily of acetyltransferases","volume":"433","author":"Vetting","year":"2005","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.apsb.2026.06.045_bib115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00018-010-0599-9","article-title":"MYST-family histone acetyltransferases: beyond chromatin","volume":"68","author":"Sapountzi","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib116","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.sbi.2011.09.005","article-title":"Understanding histone acetyltransferase Rtt109 structure and function: how many chaperones does it take?.","volume":"21","author":"D'Arcy","year":"2011","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib117","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2016.07.001","article-title":"Modulating epigenetic HAT activity for reinstating acetylation homeostasis: a promising therapeutic strategy for neurological disorders","volume":"166","author":"Ganai","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib118","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41392-025-02340-6","article-title":"Epigenetic regulation of cancer stemness","volume":"10","author":"Galassi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib119","doi-asserted-by":"crossref","first-page":"13014","DOI":"10.1074\/jbc.M115.708560","article-title":"Regulatory T cell modulation by CBP\/EP300 bromodomain inhibition","volume":"291","author":"Ghosh","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.06.045_bib120","first-page":"338","article-title":"Histone deacetylase inhibitors: can we consider potent anti-neoplastic agents for the treatment of asthma?.","volume":"42","author":"Royce","year":"2012","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcp.2017.05.006","article-title":"Therapeutic effect of Cryptotanshinone on experimental rheumatoid arthritis through downregulating p300 mediated-STAT3 acetylation","volume":"138","author":"Wang","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2026.06.045_bib122","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib123","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bcp.2004.05.042","article-title":"Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression","volume":"68","author":"Rahman","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2026.06.045_bib124","article-title":"Histone deacetylases and their inhibitors in inflammatory diseases","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2026.06.045_bib125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.apsb.2019.08.008","article-title":"Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.06.045_bib126","first-page":"6317","article-title":"RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in Saccharomyces cerevisiae. Mol Cell Biol","volume":"11","author":"Vidal","year":"1991"},{"key":"10.1016\/j.apsb.2026.06.045_bib127","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrm2346","article-title":"The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men","volume":"9","author":"Yang","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib128","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1091\/mbc.e05-01-0033","article-title":"Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins","volume":"16","author":"Michishita","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev.biochem.73.011303.073651","article-title":"The Sir2 family of protein deacetylases","volume":"73","author":"Blander","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2026.06.045_bib130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biocel.2008.09.008","article-title":"Histone deacetylase inhibitors: anticancer compounds","volume":"41","author":"Smith","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib131","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.06.045_bib132","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nbt.3130","article-title":"Acetylation site specificities of lysine deacetylase inhibitors in human cells","volume":"33","author":"Sch\u00f6lz","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.06.045_bib133","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib134","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biocel.2018.03.004","article-title":"HDAC inhibitors as epigenetic regulators for cancer immunotherapy","volume":"98","author":"Conte","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib135","doi-asserted-by":"crossref","first-page":"29483","DOI":"10.1039\/C5CP05633K","article-title":"Inhibition mechanism of SAHA in HDAC: a revisit","volume":"17","author":"Zhou","year":"2015","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.apsb.2026.06.045_bib136","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib137","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib138","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.lfs.2003.09.070","article-title":"Expression and functional characterization of recombinant human HDAC1 and HDAC3","volume":"74","author":"Li","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib139","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0006-2952(03)00411-8","article-title":"Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors","volume":"66","author":"Sasakawa","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2026.06.045_bib140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.06.045_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114419","article-title":"Targeting EZH2 for cancer therapy: from current progress to novel strategies","volume":"238","author":"Zeng","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.06.045_bib142","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The noncanonical role of EZH2 in cancer","volume":"112","author":"Huang","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib143","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.3390\/ijms21249501","article-title":"No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib144","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899599","article-title":"EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis","volume":"38","author":"Zhao","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2026.06.045_bib145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2016.03.013","article-title":"Emerging roles for polycomb proteins in cancer","volume":"36","author":"Pasini","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.apsb.2026.06.045_bib146","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib147","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41467-017-02187-8","article-title":"Ezh2 phosphorylation state determines its capacity to maintain CD8(+) T memory precursors for antitumor immunity","volume":"8","author":"He","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib148","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib149","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib150","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1021\/jm501230c","article-title":"Astemizole arrests the proliferation of cancer cells by disrupting the EZH2\u2013EED interaction of polycomb repressive complex 2","volume":"57","author":"Kong","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.06.045_bib151","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.molmed.2019.05.007","article-title":"PRMTs and arginine methylation: cancer's best-kept secret?.","volume":"25","author":"Jarrold","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib152","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib153","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib154","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.bbrc.2012.12.032","article-title":"Modulation of Epstein-Barr virus nuclear antigen 2-dependent transcription by protein arginine methyltransferase 5","volume":"430","author":"Liu","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib155","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1128\/JVI.02682-05","article-title":"Regulation of the EBNA1 Epstein-Barr virus protein by serine phosphorylation and arginine methylation","volume":"80","author":"Shire","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib156","article-title":"PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition","volume":"4","author":"Li","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186982","article-title":"PRMT5: a novel regulator of hepatitis B virus replication and an arginine methylase of HBV core","volume":"12","author":"Lubyova","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.06.045_bib158","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.29133","article-title":"PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2026.06.045_bib159","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/pathogens1010052","article-title":"Arginine methyltransferases are regulated by Epstein-Barr virus in B cells and are differentially expressed in Hodgkin's lymphoma","volume":"1","author":"Leonard","year":"2012","journal-title":"Pathogens"},{"key":"10.1016\/j.apsb.2026.06.045_bib161","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2014-12-619783","article-title":"Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation","volume":"125","author":"Alinari","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.06.045_bib162","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/v8010007","article-title":"PRMT5 is upregulated in HTLV-1-mediated T-cell transformation and selective inhibition alters viral gene expression and infected cell survival","volume":"8","author":"Panfil","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2026.06.045_bib163","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm3327","article-title":"Molecular mechanisms and potential functions of histone demethylases","volume":"13","author":"Kooistra","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib164","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41392-022-01145-1","article-title":"JMJD family proteins in cancer and inflammation","volume":"7","author":"Manni","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib165","article-title":"Modular arrangements of sequence motifs determine the functional diversity of KDM proteins","volume":"22","author":"Wang","year":"2021","journal-title":"Briefings Bioinf"},{"key":"10.1016\/j.apsb.2026.06.045_bib166","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib167","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.15252\/embr.201541113","article-title":"Histone demethylases in chromatin biology and beyond","volume":"16","author":"Dimitrova","year":"2015","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib168","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.apsb.2024.01.005","article-title":"Strategies that regulate LSD1 for novel therapeutics","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.06.045_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110392","article-title":"Emerging of lysine demethylases (KDMs): from pathophysiological insights to novel therapeutic opportunities","volume":"129","author":"Arifuzzaman","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2026.06.045_bib170","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-12-4300","article-title":"KDM4\/JMJD2 histone demethylases: epigenetic regulators in cancer cells","volume":"73","author":"Berry","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib172","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","article-title":"The biology of chromatin remodeling complexes","volume":"78","author":"Clapier","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2026.06.045_bib173","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-biophys-082520-080201","article-title":"Biophysics of chromatin remodeling","volume":"50","author":"Nodelman","year":"2021","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.apsb.2026.06.045_bib174","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies","volume":"36","author":"Centore","year":"2020","journal-title":"Trends Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib175","doi-asserted-by":"crossref","first-page":"30897","DOI":"10.1074\/jbc.R111.309302","article-title":"SWI\/SNF chromatin-remodeling factors: multiscale analyses and diverse functions","volume":"287","author":"Euskirchen","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.06.045_bib176","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/414924a","article-title":"Selectivity of chromatin-remodelling cofactors for ligand-activated transcription","volume":"414","author":"Lemon","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib177","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng.3746","article-title":"SMARCB1-mediated SWI\/SNF complex function is essential for enhancer regulation","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib178","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/ng.3958","article-title":"SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters","volume":"49","author":"Nakayama","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib179","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc3068","article-title":"SWI\/SNF nucleosome remodellers and cancer","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer\u2013biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib181","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005748","article-title":"Genome-wide transcriptional regulation mediated by biochemically distinct SWI\/SNF complexes","volume":"11","author":"Raab","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib182","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1093\/nar\/gkad907","article-title":"BRD9-mediated control of the TGF-\u03b2\/Activin\/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells","volume":"51","author":"Wang","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib183","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.30506","article-title":"Chromatin accessibility underlies synthetic lethality of SWI\/SNF subunits in ARID1A-mutant cancers","volume":"6","author":"Kelso","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.06.045_bib184","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/modpathol.3800581","article-title":"Absence of expression of SMARCB1\/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis","volume":"19","author":"Sigauke","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.apsb.2026.06.045_bib185","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2026.06.045_bib186","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1158\/1078-0432.CCR-15-2260","article-title":"Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors","volume":"22","author":"Muscat","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib187","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/0008-5472.CAN-23-2244","article-title":"Chromatin remodelers are regulators of the tumor immune microenvironment","volume":"84","author":"Chaudhri","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib188","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","article-title":"Chromatin remodellers as therapeutic targets","volume":"23","author":"Malone","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib189","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-019-1115-5","article-title":"Mammalian ISWI and SWI\/SNF selectively mediate binding of distinct transcription factors","volume":"569","author":"Barisic","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib190","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.cell.2012.04.036","article-title":"Genome-wide nucleosome specificity and directionality of chromatin remodelers","volume":"149","author":"Yen","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib191","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s13046-021-02151-x","article-title":"The emerging role of ISWI chromatin remodeling complexes in cancer","volume":"40","author":"Li","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib192","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087448","article-title":"Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5","volume":"9","author":"Dluhosova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.06.045_bib193","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.06619-11","article-title":"Nucleosome remodeler SNF2L suppresses cell proliferation and migration and attenuates Wnt signaling","volume":"32","author":"Eckey","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib194","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1097-2765(03)00273-9","article-title":"Crystal structure and functional analysis of a nucleosome recognition module of the remodeling factor ISWI","volume":"12","author":"Gr\u00fcne","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib195","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46057","article-title":"Cryo-EM structures of remodeler-nucleosome intermediates suggest allosteric control through the nucleosome","volume":"8","author":"Armache","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.06.045_bib196","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature09947","article-title":"Structure and mechanism of the chromatin remodelling factor ISW1a","volume":"472","author":"Yamada","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib197","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1541-7786.MCR-18-1121","article-title":"GSK2801, a BAZ2\/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer","volume":"17","author":"Bevill","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib198","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.047662","article-title":"miRNA interplay: mechanisms and consequences in cancer","volume":"14","author":"Hill","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.apsb.2026.06.045_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2026.06.045_bib200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.apsb.2015.01.002","article-title":"Emerging role of microRNAs in lipid metabolism","volume":"5","author":"Yang","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.06.045_bib201","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib202","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/ng.848","article-title":"Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters","volume":"43","author":"Hung","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cell.2011.09.028","article-title":"A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA","volume":"147","author":"Cesana","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib204","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1242\/dev.048181","article-title":"Kcnq1ot1 noncoding RNA mediates transcriptional gene silencing by interacting with Dnmt1","volume":"137","author":"Mohammad","year":"2010","journal-title":"Development"},{"key":"10.1016\/j.apsb.2026.06.045_bib205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003705","article-title":"The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation","volume":"9","author":"Beckedorff","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib206","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.3390\/ijms16023251","article-title":"Neighboring gene regulation by antisense long non-coding RNAs","volume":"16","author":"Villegas","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib207","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrm3679","article-title":"RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts","volume":"14","author":"Geisler","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib208","first-page":"48","article-title":"Molecular mechanisms of long ncRNAs in neurological disorders","volume":"5","author":"Vu\u010di\u0107evi\u0107","year":"2014","journal-title":"Front Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib209","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s11011-021-00739-y","article-title":"Emerging role of non-coding RNA in health and disease","volume":"36","author":"Bhatti","year":"2021","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.apsb.2026.06.045_bib210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2019.03.021","article-title":"Extracellular miRNAs as activators of innate immune receptors","volume":"452","author":"Bosisio","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.06.045_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.064","article-title":"Self-recognition of an inducible host lncRNA by RIG-I feedback restricts innate immune response","volume":"173","author":"Jiang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib212","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ncrna.2023.07.002","article-title":"MiRNAs and lncRNAs in the regulation of innate immune signaling","volume":"8","author":"Gareev","year":"2023","journal-title":"Noncoding RNA Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib213","doi-asserted-by":"crossref","first-page":"9407","DOI":"10.7150\/thno.48520","article-title":"Roles of long non-coding RNAs and emerging RNA-binding proteins in innate antiviral responses","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2026.06.045_bib214","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib215","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.270959.115","article-title":"Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss","volume":"30","author":"Arun","year":"2016","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2026.06.045_bib216","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/0008-5472.CAN-12-2850","article-title":"The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells","volume":"73","author":"Gutschner","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib217","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.10.054","article-title":"Long noncoding RNA GMAN, up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of Ephrin A1 by competitively binding GMAN-AS","volume":"156","author":"Zhuo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2026.06.045_bib218","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah7111","article-title":"CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells","volume":"355","author":"Liu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.045_bib219","doi-asserted-by":"crossref","first-page":"15805","DOI":"10.1073\/pnas.0707628104","article-title":"MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B","volume":"104","author":"Fabbri","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.06.045_bib220","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1039\/B803580F","article-title":"Long-range chromosomal interactions and gene regulation","volume":"4","author":"Miele","year":"2008","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.apsb.2026.06.045_bib221","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCRESAHA.109.200774","article-title":"Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy","volume":"105","author":"Turunen","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib222","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000258","article-title":"Bidirectional transcription directs both transcriptional gene activation and suppression in human cells","volume":"4","author":"Morris","year":"2008","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib223","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/cvr\/cvr097","article-title":"Non-coding RNAs as regulators of gene expression and epigenetics","volume":"90","author":"Kaikkonen","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib224","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib225","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.06.045_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib227","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018663","article-title":"Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure","volume":"6","author":"Qi","year":"2014","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib228","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd1930","article-title":"Epigenetic therapy of cancer: past, present and future","volume":"5","author":"Yoo","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib229","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.apsb.2022.12.019","article-title":"The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.06.045_bib230","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.3390\/cancers15112883","article-title":"Mutant IDH in gliomas: role in cancer and treatment options","volume":"15","author":"Solomou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.06.045_bib231","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-019-0173-z","article-title":"Isocitrate dehydrogenase inhibitors in acute myeloid leukemia","volume":"7","author":"Liu","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib232","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib233","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/noy146","article-title":"Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide","volume":"21","author":"Yamashita","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib234","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib235","doi-asserted-by":"crossref","first-page":"7768","DOI":"10.1038\/ncomms8768","article-title":"D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2","volume":"6","author":"Lin","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib236","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.045_bib237","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib238","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.apsb.2026.06.045_bib239","article-title":"Research progress and applications of epigenetic biomarkers in cancer","volume":"15","author":"Gao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.06.045_bib240","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","article-title":"Targeting DNA methylation","volume":"15","author":"Issa","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib241","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib242","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib243","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2014.02.011","article-title":"Phase I\/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression","volume":"84","author":"Reguart","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib244","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1476-4598-7-70","article-title":"Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells","volume":"7","author":"Dejligbjerg","year":"2008","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2026.06.045_bib246","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10637-008-9131-6","article-title":"Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer","volume":"26","author":"Vansteenkiste","year":"2008","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.apsb.2026.06.045_bib247","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell Non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib248","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib249","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/epi-2023-0142","article-title":"Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements","volume":"15","author":"Singh","year":"2023","journal-title":"Epigenomics"},{"key":"10.1016\/j.apsb.2026.06.045_bib250","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.06.045_bib251","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","article-title":"Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies","volume":"81","author":"Wajapeyee","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib252","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/genes12020208","article-title":"Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing","volume":"12","author":"Majchrzak-Celi\u0144ska","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.apsb.2026.06.045_bib253","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib254","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib255","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2013.248","article-title":"Clonal evolution in hematological malignancies and therapeutic implications","volume":"28","author":"Landau","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2026.06.045_bib256","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","article-title":"Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming","volume":"21","author":"Liang","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib257","doi-asserted-by":"crossref","first-page":"20167","DOI":"10.1021\/acsnano.4c03034","article-title":"Dual-responsive epigenetic inhibitor nanoprodrug combined with oncolytic virus synergistically boost cancer immunotherapy by igniting gasdermin E-mediated pyroptosis","volume":"18","author":"Wang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.06.045_bib258","doi-asserted-by":"crossref","first-page":"14981","DOI":"10.1073\/pnas.0803988105","article-title":"Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis","volume":"105","author":"Nguy\u00ean","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.06.045_bib259","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1158\/1078-0432.CCR-06-1228","article-title":"A novel HSV-1 virus, JS1\/34.5-\/47-, purges contaminating breast cancer cells from bone marrow","volume":"12","author":"Hu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12935-022-02583-1","article-title":"Win or loss?. Combination therapy does improve the oncolytic virus therapy to pancreatic cancer","volume":"22","author":"Luo","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.apsb.2026.06.045_bib261","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jnci\/djj003","article-title":"Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication","volume":"98","author":"Aghi","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2026.06.045_bib262","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/0008-5472.CAN-12-3056","article-title":"Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation","volume":"73","author":"Muthana","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib263","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1089\/10430349950016410","article-title":"Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer","volume":"10","author":"Toyoizumi","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib264","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2020-0005","article-title":"Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)","volume":"7","author":"Sun","year":"2020","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.apsb.2026.06.045_bib265","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2019-0012","article-title":"Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)","volume":"6","author":"Perez","year":"2019","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.apsb.2026.06.045_bib266","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2026.06.045_bib267","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cytogfr.2010.03.002","article-title":"Oncolytic viruses and histone deacetylase inhibitors\u2013a multi-pronged strategy to target tumor cells","volume":"21","author":"Nguyen","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.apsb.2026.06.045_bib268","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib269","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002373","article-title":"Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling","volume":"9","author":"Varudkar","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib270","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1099\/vir.0.82242-0","article-title":"Exchange of P\/V genes between two non-cytopathic simian virus 5 variants results in a recombinant virus that kills cells through death pathways that are sensitive to caspase inhibitors","volume":"87","author":"Dillon","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib271","doi-asserted-by":"crossref","first-page":"10109","DOI":"10.1128\/JVI.76.20.10109-10121.2002","article-title":"Naturally occurring substitutions in the P\/V gene convert the noncytopathic paramyxovirus simian virus 5 into a virus that induces alpha\/beta interferon synthesis and cell death","volume":"76","author":"Wansley","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib272","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.83391-0","article-title":"Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures","volume":"89","author":"Randall","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib273","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.186.6.967","article-title":"A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system","volume":"186","author":"Castelli","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib274","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/JVI.02023-07","article-title":"Paramyxovirus-induced shutoff of host and viral protein synthesis: role of the P and V proteins in limiting PKR activation","volume":"82","author":"Gainey","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib275","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/vim.2004.17.516","article-title":"Vesicular stomatitis virus as an oncolytic vector","volume":"17","author":"Barber","year":"2004","journal-title":"Viral Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib276","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1007\/s11033-019-04799-3","article-title":"M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells","volume":"46","author":"Gray","year":"2019","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.apsb.2026.06.045_bib277","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jss.2019.07.032","article-title":"Immune effects of M51R vesicular stomatitis virus treatment of carcinomatosis from colon cancer","volume":"245","author":"Day","year":"2020","journal-title":"J Surg Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib278","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012138","article-title":"Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy","volume":"13","author":"Russo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib279","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113843","article-title":"Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma","volume":"155","author":"Kawamura","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2026.06.045_bib281","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/glycob\/cwl083","article-title":"Virus-induced transcriptional activation of host FUT genes associated with neo-expression of Ley in cytomegalovirus-infected and sialyl-lex in varicella-zoster virus-infected diploid human cells","volume":"17","author":"Nystr\u00f6m","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.apsb.2026.06.045_bib282","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00705-009-0580-9","article-title":"Inhibition of protein deacetylation augments herpes simplex virus type 1-activated transcription of host fucosyltransferase genes associated with virus-induced sLex expression","volume":"155","author":"Nord\u00e9n","year":"2010","journal-title":"Arch Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib283","article-title":"Interferon and interferon-stimulated genes in HBV treatment","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib284","doi-asserted-by":"crossref","first-page":"13421","DOI":"10.1073\/pnas.0801613105","article-title":"miR-34a repression of SIRT1 regulates apoptosis","volume":"105","author":"Yamakuchi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.06.045_bib285","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1947601912475079","article-title":"The roles of SIRT1 in cancer","volume":"4","author":"Lin","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib286","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.bbapap.2010.05.002","article-title":"SIRT1 and p53, effect on cancer, senescence and beyond","volume":"1804","author":"Yi","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2026.06.045_bib287","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2199-13-4","article-title":"Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells","volume":"13","author":"Li","year":"2012","journal-title":"BMC Mol Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib288","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1128\/JVI.07056-11","article-title":"The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells","volume":"86","author":"Forte","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.06.045_bib289","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2006-06-027599","article-title":"Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia","volume":"108","author":"Kamphuis","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.06.045_bib290","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/mt.2012.265","article-title":"HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy","volume":"21","author":"Bridle","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib291","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2020002297","article-title":"Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy","volume":"4","author":"Islam","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.apsb.2026.06.045_bib292","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3892\/ijo.2016.3675","article-title":"Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus","volume":"49","author":"Ellerhoff","year":"2016","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib293","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/137163","article-title":"Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells","volume":"2012","author":"Kasman","year":"2012","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib294","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41375-025-02617-3","article-title":"An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy","volume":"39","author":"Stewart","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2026.06.045_bib295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014462","article-title":"Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors","volume":"5","author":"MacTavish","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.06.045_bib296","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s42003-024-06389-x","article-title":"Multi-omics analysis reveals the dynamic interplay between Vero host chromatin structure and function during vaccinia virus infection","volume":"7","author":"Venu","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib297","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1038\/s41467-024-48370-6","article-title":"Multiscale modelling of chromatin 4D organization in SARS-CoV-2 infected cells","volume":"15","author":"Chiariello","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib298","article-title":"BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma","volume":"6","author":"Guo","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib299","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00109-012-0985-x","article-title":"Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model","volume":"91","author":"Lou","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.apsb.2026.06.045_bib300","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.06.045_bib301","article-title":"Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response","volume":"13","author":"Wu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.apsb.2026.06.045_bib302","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41401-025-01639-y","article-title":"DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I\/MDA5-MAVS to enhance antitumor immunity","volume":"47","author":"Tu","year":"2026","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2026.06.045_bib303","article-title":"Targeting HDAC and PARP enhances STING-dependent antitumor immunity in STING-deficient tumor","volume":"12","author":"Mao","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.06.045_bib304","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: from mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.06.045_bib305","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib306","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.apsb.2026.06.045_bib307","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib308","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib309","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib310","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib311","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib312","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","article-title":"Combining epigenetic and immunotherapy to combat cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib313","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib314","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib315","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.32604\/or.2025.067824","article-title":"Immune checkpoint inhibitors combined with oncolytic virotherapy: synergy, heterogeneity, and safety in cancer treatment","volume":"33","author":"Feng","year":"2025","journal-title":"Oncol Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib316","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473590","article-title":"Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials","volume":"45","author":"Azenkot","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.apsb.2026.06.045_bib317","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib318","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12016-022-08956-8","article-title":"Epigenetic dysregulation in autoimmune and inflammatory skin diseases","volume":"63","author":"Gibson","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.apsb.2026.06.045_bib319","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib320","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib321","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41698-024-00717-4","article-title":"Therapeutic approaches to modulate the immune microenvironment in gliomas","volume":"8","author":"Sarantopoulos","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2025.02.019","article-title":"Base-pair resolution reveals clustered R-loops and DNA damage-susceptible R-loops","volume":"85","author":"Li","year":"2025","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib323","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt.3853","article-title":"CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome","volume":"35","author":"Klann","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.06.045_bib324","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Nu\u00f1ez","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.045_bib325","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1101\/gr.233049.117","article-title":"A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs","volume":"28","author":"Pflueger","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib326","article-title":"A genome-scale CRISPR knock-out screen identifies microRNA-5197-5p as a promising radiosensitive biomarker in colorectal cancer","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2026.06.045_bib327","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14422","article-title":"LncRNA AK023948 is a positive regulator of AKT","volume":"8","author":"Koirala","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib328","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1126\/science.aaf7613","article-title":"High-resolution interrogation of functional elements in the noncoding genome","volume":"353","author":"Sanjana","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.045_bib329","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-020-01995-4","article-title":"CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma","volume":"21","author":"Liu","year":"2020","journal-title":"Genome Biol"},{"key":"10.1016\/j.apsb.2026.06.045_bib330","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature23451","article-title":"Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood","volume":"548","author":"Joung","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.045_bib331","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nbt.3715","article-title":"Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library","volume":"34","author":"Zhu","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.06.045_bib332","doi-asserted-by":"crossref","DOI":"10.1002\/adma.70627","article-title":"Engineering CRISPR system-based bacterial outer membrane vesicle potentiates T cell immunity for enhanced cancer immunotherapy","volume":"37","author":"Wang","year":"2025","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.06.045_bib333","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41467-024-44941-9","article-title":"Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib334","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.045_bib335","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41467-024-45422-9","article-title":"High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","volume":"15","author":"Xue","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.045_bib336","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-017-0218-5","article-title":"Combination immunotherapy: a road map","volume":"5","author":"Ott","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.06.045_bib337","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41592-024-02360-0","article-title":"Single-cell EpiChem jointly measures drug-chromatin binding and multimodal epigenome","volume":"21","author":"Dong","year":"2024","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.06.045_bib338","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2024025618","article-title":"Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia","volume":"145","author":"Cui","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.06.045_bib339","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1158\/0008-5472.CAN-13-3472","article-title":"Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability","volume":"74","author":"Kuruppu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.045_bib340","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jcis.2024.05.175","article-title":"Platelet membrane-coated oncolytic vaccinia virus with indocyanine green for the second near-infrared imaging guided multi-modal therapy of colorectal cancer","volume":"671","author":"Huang","year":"2024","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib341","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.3390\/app15126578","article-title":"From genomics to AI: revolutionizing precision medicine in oncology","volume":"15","author":"Calvino","year":"2025","journal-title":"Appl Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib342","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1186\/s12967-025-07308-2","article-title":"Exploiting artificial intelligence in precision oncology: an updated comprehensive review","volume":"23","author":"Goda","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2026.06.045_bib343","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311443","article-title":"Deep generative AI for multi-target therapeutic design: toward self-improving drug discovery framework","volume":"26","author":"Kang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.06.045_bib344","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41592-025-02685-4","article-title":"Digitalized organoids: integrated pipeline for high-speed 3D analysis of organoid structures using multilevel segmentation and cellular topology","volume":"22","author":"Ong","year":"2025","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.06.045_bib345","article-title":"A compound screen based on isogenic hESC-derived \u03b2 cell reveals an inhibitor targeting ZnT8-mediated zinc transportation to protect pancreatic \u03b2 cell from stress-induced cell death","volume":"12","author":"Hu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.06.045_bib346","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct Target Ther"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:14:01Z","timestamp":1789600441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526004028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":346,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2211383526004028"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.06.045","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuning epigenetics to enhance cancer virotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.06.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}